NCT03424122 2025-08-21INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)Incyte CorporationPhase 1 Completed50 enrolled